Bosnia and HerzegovinaTuberculosis profile
Population  2014 3.8 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.15 (0.13–0.16) 3.8 (3.5–4.2)
Mortality (HIV+TB only) 0 (–) 0 (–)
Prevalence  (includes HIV+TB) 2.4 (1.2–4.1) 64 (32–107)
Incidence  (includes HIV+TB) 1.6 (1.2–2.1) 42 (31–55)
Incidence (HIV+TB only) <0.01 (<0.01–<0.01) 0.07 (0.05–0.1)
         
Case detection, all forms (%) 75 (57–100)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 0 (0–0.57) 1.6 (0.04–8.5)
MDR-TB cases among notified pulmonary
TB cases
0 (0–5) 2 (0–9)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 613   59
Pulmonary, clinically diagnosed 328   43
Extrapulmonary 147   6
       
Total new and relapse 1 196    
Previously treated, excluding relapses 0    
Total cases notified 1 196    
Among 1 196 new and relapse cases:
15 (1%) cases aged under 15 years; male:female ratio: 1.4
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 613 (100%) 59 (55%) 672
Laboratory-confirmed RR-/MDR-TB cases     4
Patients started on MDR-TB treatment ***     3
TB/HIV 2014 Number (%)
TB patients with known HIV status 194 (16)
HIV-positive TB patients    
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART)    
HIV-positive people screened for TB 131  
HIV-positive people provided with IPT 2  
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (82) 1 261
Previously treated cases, excluding relapse, registered in 2013   0
HIV-positive TB cases, all types, registered in 2013   0
RR-/MDR-TB cases started on second-line treatment in 2012 (43) 7
XDR-TB cases started on second-line treatment in 2012   0
Laboratories 2014  
Smear (per 100 000 population) 0.4
Culture (per 5 million population) 15.7
Drug susceptibility testing (per 5 million population) 9.2
Sites performing Xpert MTB/RIF 0
Is second-line drug susceptibility testing available? Yes, outside
country
Financing TB control 2015  
National TB programme budget (US$ millions) 12
% Funded domestically 86%
% Funded internationally 14%
% Unfunded 0%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-09-25 Data: www.who.int/tb/data